Aducanumab Lowers Amyloid Plaque Associated with Alzheimer’s, Extension Trial Shows

Aducanumab Lowers Amyloid Plaque Associated with Alzheimer’s, Extension Trial Shows
Aducanumab reduced deposits of the amyloid plaque associated with Alzheimer's disease in the brains of early-stage patients who took part in a three-year extension trial, Biogen reports. After the study ended, deposits of the protein were lower in many patients' brains than the level that a scan would identify as constituting Alzheimer's, researchers said. The treatment is now in Phase 3 clinical treats. Imaging showed that a fourth of the 143 patients in the extension study experienced brain swelling from the treatment. But most did not experience symptoms from it, and it was temporary in the majority of cases. Researchers in the Phase 1 trial (NCT01677572) randomly assigned patients with early-stage or mild Alzheimer’s to various doses of aducanumab or a placebo. The 143 patients in the extension study were divided into four groups. One consisted of 18 people whom researchers assigned to an increasing-dose schedule of aducanumab or a placebo for 12 months. Patients on the placebo were switched to aducanumab after the first year. Biogen followed these patients for two years. The researchers followed 69 patients who received various-strength fixed doses for 36 months. Another group included patients who received a very low dose of adcanumab during the first year, and higher doses in the extension study. All patients who were on a placebo during the Phase 1 clinical trial received adcanumab during the extension. Biogen reported in a press release that the treatment lowered amyloid-beta brain deposits in a dose- and time-dependent manner, mean
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *